利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

54 条记录 (耗时 0.038 秒)

    Memantine intravitreal implants
    41.
    发明申请
    Memantine intravitreal implants 审中-公开
    美金刚玻璃体内植入物

    公开(公告)号：US20050244473A1

    公开(公告)日：2005-11-03

    申请号：US11117879

    申请日：2005-04-29

    申请人： Patrick Hughes ,  Lon Spada ,  Hiroshi Sugimoto ,  Wendy Blanda ,  James Chang

    发明人： Patrick Hughes ,  Lon Spada ,  Hiroshi Sugimoto ,  Wendy Blanda ,  James Chang

    IPC分类号： A61K9/00 ,  A61K31/13 ,  A61F2/00

    CPC分类号： A61K9/0051

    摘要： Biocompatible intraocular implants include an anti-excitotoxic agent and a biodegradable polymer that is effective to facilitate release of the anti-excitotoxic agent into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy.

    摘要翻译： 生物相容性眼内植入物包括抗兴奋性毒性剂和可生物降解的聚合物，其有效促进抗兴奋性毒性剂长时间释放到眼睛中。 植入物的治疗剂可以与可生物降解的聚合物基质相关，例如基本上不含聚乙烯醇的基质。 植入物可以放置在眼睛中以治疗或减少一种或多种眼部病症的发生，例如视网膜损伤，包括青光眼和增生性玻璃体视网膜病变。

    Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
    42.
    发明申请
    Intraocular drug delivery systems containing excipients with reduced toxicity and related methods 审中-公开
    含有降低毒性的赋形剂和相关方法的眼内药物递送系统

    公开(公告)号：US20050244472A1

    公开(公告)日：2005-11-03

    申请号：US11092122

    申请日：2005-03-28

    申请人： Patrick Hughes ,  Laurent Delahaye ,  Michele Boix

    发明人： Patrick Hughes ,  Laurent Delahaye ,  Michele Boix

    IPC分类号： A61F2/00 ,  A61F9/00 ,  A61K9/00 ,  A61K9/16 ,  A61K31/724 ,  A61K39/395 ,  A61K47/34 ,  A61K47/40 ,  A61K47/48 ,  A61K48/00

    CPC分类号： A61K9/0051 ,  A61F9/0008 ,  A61F9/0017 ,  A61K9/1647 ,  A61K31/724 ,  A61K47/34 ,  A61K47/40

    摘要： Drug delivery systems suitable for administration into the interior of an eye of a person or animal are described. The present systems include one or more components which are effective in improving a release profile of a drug from the system, improving the stability of the drug, and improving the ocular tolerability of the drug. The present systems include one or more therapeutic agents in amounts effective in providing a desired therapeutic effect when placed in an eye, and an excipient component with reduced toxicity to retinal cells. The excipient component may include a cyclodextrin component that may be complexed with the therapeutic agents to provide advantages over existing intraocular drug delivery systems. The cyclodextrin component of the present systems have a reduced toxicity relative to benzyl alcohol or polysorbate 80. The drug delivery systems include one or more drug delivery elements such as microparticles, bioerodible implants, non-bioerodible implants, and combinations thereof. Methods of using and producing the drug delivery systems are also described.

    摘要翻译： 描述了适合施用于人或动物的眼睛内部的药物递送系统。 本发明的系统包括一种或多种有效改善药物从系统释放曲线，提高药物稳定性和改善药物的眼睛耐受性的成分。 本发明的系统包括当放置在眼睛中时有效提供所需治疗效果的量的一种或多种治疗剂和对视网膜细胞毒性降低的赋形剂组分。 赋形剂组分可以包括可与治疗剂复合的环糊精组分，以提供优于现有的眼内药物递送系统的优点。 本系统的环糊精组分相对于苯甲醇或聚山梨酸酯80具有降低的毒性。药物递送系统包括一种或多种药物递送元件，例如微粒，生物侵蚀性植入物，非生物侵蚀性植入物及其组合。 还描述了使用和产生药物递送系统的方法。

    Stabilized biodegradable neurotoxin implants
    43.
    发明申请
    Stabilized biodegradable neurotoxin implants 有权
    稳定的生物降解神经毒素植入物

    公开(公告)号：US20050232966A1

    公开(公告)日：2005-10-20

    申请号：US10826441

    申请日：2004-04-15

    申请人： Patrick Hughes ,  Orest Olejnik

    发明人： Patrick Hughes ,  Orest Olejnik

    IPC分类号： A61K39/02 ,  A61K39/08 ,  A61L31/06 ,  A61L31/16

    CPC分类号： A61K9/0024 ,  A61K9/0051 ,  A61K9/204 ,  A61K38/4893

    摘要： Biodegradable neurotoxin implants and methods of making and using such implants are provided. Biodegradable neurotoxin implants include a neurotoxin, a biodegradable polymer component, and an acidity regulating component. The biodegradable polymer component is effective in controlling the release of the neurotoxin from the implant when the implant is located in a patient's body. The acidity regulating component is effective in maintaining a pH of the implant in a desired range that may be effective in stabilizing the neurotoxin as the implant biodegrades when the implant is located in a patient's body. In one embodiment, an implant includes a botulinum toxin, a biodegradable polymer, and either monomers from which a biodegradable polymer is derived or oligomers including monomeric units substantially identical to a monomer from which a biodegradable polymer is derived, or a combination of such monomers and oligomers. The oligomers and biodegradable polymer may be derived from a single type of monomer. The implants disclosed herein may be administered to a human or animal patient in which a therapeutic effect is desired for prolonged periods of time.

    摘要翻译： 提供了可生物降解的神经毒素植入物和制造和使用这种植入物的方法。 可生物降解的神经毒素植入物包括神经毒素，可生物降解的聚合物组分和酸度调节组分。 当植入物位于患者体内时，可生物降解的聚合物组分有效地控制来自植入物的神经毒素的释放。 酸性调节组分有效地将植入物的pH保持在期望的范围内，当植入物位于患者体内时，当植入物生物降解时，稳定神经毒素是有效的。 在一个实施方案中，植入物包括肉毒杆菌毒素，可生物降解聚合物，以及衍生生物可降解聚合物的单体或包含单体单元的寡聚物，所述单体基本上与衍生可生物降解聚合物的单体相同，或这些单体和 低聚物。 低聚物和可生物降解的聚合物可以衍生自单一类型的单体。 本文公开的植入物可以施用于需要长时间治疗效果的人或动物患者。

    Compositions and methods comprising memantine and polyanionic polymers
    44.
    发明申请
    Compositions and methods comprising memantine and polyanionic polymers 审中-公开
    包括美金刚和聚阴离子聚合物的组合物和方法

    公开(公告)号：US20050147584A1

    公开(公告)日：2005-07-07

    申请号：US10752125

    申请日：2004-01-05

    申请人： Patrick Hughes ,  Orest Olejnik

    发明人： Patrick Hughes ,  Orest Olejnik

    IPC分类号： A61K31/13 ,  A61K38/17 ,  A61K31/716 ,  A61K31/717 ,  A61K31/728 ,  A61K31/785

    CPC分类号： A61K31/13

    摘要： Disclosed herein are aqueous solutions comprising a neuroprotective amine related to adamantane and a polyanionic polymer. Also disclosed herein are methods of treating glaucoma and methods of treating a disease or a condition wherein migration or proliferation of retinal pigment epithelium or glial cells causes or contributes to the cause of said disease or condition.

    摘要翻译： 本文公开了包含与金刚烷和聚阴离子聚合物相关的神经保护胺的水溶液。 本文还公开了治疗青光眼的方法和治疗疾病或其中视网膜色素上皮细胞或神经胶质细胞的迁移或增殖导致或有助于所述疾病或病症原因的病症的方法。

    Methods and compositions for the administration of prodrugs of proton pump inhibitors
    48.
    发明申请
    Methods and compositions for the administration of prodrugs of proton pump inhibitors 审中-公开
    用于施用质子泵抑制剂前药的方法和组合物

    公开(公告)号：US20070060621A1

    公开(公告)日：2007-03-15

    申请号：US10554151

    申请日：2005-01-13

    申请人： Patrick Hughes

    发明人： Patrick Hughes

    IPC分类号： A61K31/4439 ,  C07D403/02

    CPC分类号： A61K31/4439 ,  A61K9/4858 ,  A61K47/02 ,  A61K47/12

    摘要： Disclosed herein are methods, compositions, and dosage forms related to prodrugs of a proton pump inhibitors wherein said compositions and dosage forms do not comprise a salt of phosphoric acid. Principles related to the use of various anions and buffers in relation to these prodrugs are also disclosed.

    摘要翻译： 本文公开了与质子泵抑制剂的前药相关的方法，组合物和剂型，其中所述组合物和剂型不包含磷酸盐。 还公开了与这些前药相关的各种阴离子和缓冲液的使用相关的原理。

    Anti-angiogenic sustained release intraocular implants and related methods
    49.
    发明申请
    Anti-angiogenic sustained release intraocular implants and related methods 审中-公开
    抗血管生成持续释放眼内植入物及相关方法

    公开(公告)号：US20070059336A1

    公开(公告)日：2007-03-15

    申请号：US11364687

    申请日：2006-02-27

    申请人： Patrick Hughes ,  Thomas Malone ,  Gerald De Vries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Peter Baciu ,  Scott Whitcup

    发明人： Patrick Hughes ,  Thomas Malone ,  Gerald De Vries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Peter Baciu ,  Scott Whitcup

    IPC分类号： A61K38/18 ,  A61K39/395

    CPC分类号： A61K48/0041 ,  A61K9/0051

    摘要： Biocompatible intraocular drug delivery systems include a anti-angiogenic therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three dimensional structure but retain its therapeutic activity. The therapeutic agent may be selected from the group consisting of anti-angiogenesis peptides, hormones and nucleic acid agents. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.

    摘要翻译： 生物相容性眼内药物递送系统包括抗血管生成治疗剂和植入物，微粒，多种植入物或微粒形式的聚合物组分及其组合。 治疗剂以生物活性形式释放，例如，当释放到患者的眼睛中时，治疗剂可以保持其三维结构，或者治疗剂可以具有改变的三维结构，但保持其治疗活性。 治疗剂可以选自抗血管生成肽，激素和核酸试剂。 植入物可以置于眼睛中以治疗或减少一种或多种眼部病症的发生，例如视网膜损伤，包括青光眼和增生性玻璃体视网膜病变等。

    Methods for treating ocular conditions with cyclic lipid containing microparticles
    50.
    发明申请
    Methods for treating ocular conditions with cyclic lipid containing microparticles 有权
    用含脂质的微粒治疗眼部病症的方法

    公开(公告)号：US20060246145A1

    公开(公告)日：2006-11-02

    申请号：US11371118

    申请日：2006-03-08

    申请人： James Chang ,  Patrick Hughes ,  Chin-Ming Chang

    发明人： James Chang ,  Patrick Hughes ,  Chin-Ming Chang

    IPC分类号： A61K9/50 ,  B01J13/04 ,  B01J13/02 ,  A61K9/16

    CPC分类号： A61K31/5575 ,  A61K9/0048 ,  A61K9/0051 ,  A61K9/107 ,  A61K9/1075 ,  A61K9/146 ,  A61K9/1647 ,  A61K9/1694 ,  A61K31/165 ,  A61K47/34 ,  B01J13/04 ,  B01J13/06

    摘要： Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.

    摘要翻译： 生物相容的微粒包括眼科活性的环状脂质组分和可生物降解的聚合物，当放置在结膜下空间中时，有效地促进环状脂质成分延长眼睛部分的时间。 环状脂质组分可与可生物降解的聚合物基质相结合，例如两种可生物降解聚合物的基质。 或者，环状脂质组分可以被聚合物组分包封。 本发明的微粒包括水包油乳化微粒。 结膜下施用的微粒可用于治疗或减少眼部疾病如青光眼或年龄相关性黄斑变性的至少一种症状。